Across multiple preclinical models, including xenogeneic adoptive transfer systems, these cells have consistently exhibited sustained antitumor activity against MM and enhanced ADCC in the presence of therapeutic anti-CD38 antibodies [115,116]. The gene discussed is CD38; the disease is Miyoshi myopathy.